Monitoring Valproic Acid Levels in Patients on Anticonvulsant Therapy

Introduction to Valproic Acid Monitoring

• The American Society of Clinical Oncology recommends monitoring valproic acid levels to explore failure to control epileptic activity, assess compliance, or for differential diagnosis of potential drug-related side effects in patients on valproic acid as the primary anticonvulsant 1, 2

Preferred Anticonvulsant Options

• The National Comprehensive Cancer Network suggests levetiracetam as the drug of first choice at most neuro-oncology centers due to its favorable side effect profile 1
• Levetiracetam and lamotrigine are preferred options for seizure management in brain tumor patients because of their efficacy and overall good tolerability 1, 2
• The European Society for Medical Oncology recommends avoiding enzyme-inducing anticonvulsants in patients with brain tumors 1

Patient Management

• In patients with brain tumors on chemotherapy, levetiracetam is generally better tolerated than valproic acid due to lower risk of hematologic toxicities 5, 6
• The American Academy of Neurology suggests monitoring valproic acid levels only for standard clinical indications, such as seizure control assessment, compliance verification, or side effect evaluation, in patients on both levetiracetam and valproic acid 1, 2

Side Effect Monitoring

• Valproic acid use has been associated with complications such as thrombocytopenia and hepatotoxicity that require regular monitoring 3, 4
• Levetiracetam is primarily associated with psychiatric side effects, which remain a concern in some patients 1